Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder

Inclusion Criteria:

- Males > 18 years of age with a primary (or co-principal) psychiatric diagnosis of
social anxiety disorder (SAD), as defined by Diagnostic and Statistical Manual-IV
(DSM-IV) criteria;

- Current Liebowitz Social Anxiety Scale (LSAS) score > 60, which is a clinical
threshold for SAD symptoms;

- Comorbid present DSM-IV Major Depression, Dysthymia, Specific Phobia, or any of the
other anxiety disorders as diagnosed by DSM-IV criteria will be permitted as long as
SAD is primary (the disorder that is most distressing to the patient). Inclusion of
patients with comorbidity will permit accrual of a more clinically relevant patient
population;

- Willingness to participate in and comply with the study procedures as indicated by
signing the informed consent form.

Exclusion Criteria:

- Subjects with a serious medical illness for which hospitalization may be likely within
the next three months;

- Subjects with a current diagnosis of schizophrenia, psychotic disorders, bipolar
disorder, mental disorder due to a medical condition or substance, substance abuse or
dependence, as diagnosed by DSM-IV criteria;

- Concurrent use of other psychotropic medications is excluded, except for
antidepressants that have been taken at a stable dose for at least 2 weeks;

- Active suicidal or homicidal ideation or suicide attempts within the past six months
requiring hospitalization;

- Subjects with significant nasal pathology (atrophic rhinitis, recurrent nose bleeds,
or history of hypophysectomy);

- Smokers who smoke more than 15 cigarettes per day;

- Those who smoke cigarettes or have caffeine or alcohol within 24 hours of the study
visit.